Purchase this article with an account.
Mi Sun Sung, Zhengri Li, Jee Myung Yang, Ji Suk Choi, In-Cheon You, Kyung Chul Yoon; Effectiveness of Topical AICA-Ribonucleotide in a Mouse Model of Experimental Dry Eye. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3652. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the efficacy of a topical AICA-Ribonucleotide (AICAR) in a mouse model of experimental dry eye (EDE)
Eye drops consisting of 0.001% and 0.01% AICAR, or 0.05% cyclosporin (CsA) were applied in EDE. Tear volume, tear film break-up time (TBUT) and corneal fluorescein staining scores were measured at 10 days after treatment. Levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, monokine induced by interferon-γ (MIG) and Interferon gamma-induced protein 10 (IP-10) were measured in the conjunctiva using a multiplex immunobead assay. Periodic acid-Schiff staining, immunofluorescence staining and flow cytometry were also performed.
Mice treated with 0.01% AICAR showed a significant improvement in tear volume, TBUT and corneal fluorescein staining scores compared with the EDE control and other treatment groups. A significant decrease in the levels of IL-1β, IL-6, TNF-α, IFN-γ, MIG and IP-10 and the number of CD11b+ and CD4+CXCR3+ cells and an increase in goblet cell density was observed in the 0.01% AICAR-treated group, compared with the control and other treatment groups. 0.05% CsA also led to an improvement in the tear and corneal signs and inflammatory molecules compared with the control. However, there were no significant differences in all parameters between the 0.001% AICAR and EDE control groups.
Topical application of 0.01% AICAR could markedly improve clinical signs and decrease inflammation in the ocular surface of EDE, suggesting that AICAR eye drops may be used as a therapeutic agent for dry eye disease.
This PDF is available to Subscribers Only